(Q36222013)

12 August 2017

1 reference

title

Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection (English)

1 reference

12 August 2017

1 reference

1 reference

1 reference

Susan S Kaplan

1

1 reference

PubMed ID

16086645

12 August 2017

Charles B Hicks

series ordinal

2

1 reference

PubMed ID

16086645

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

1 reference

12 August 2017

6

1 reference

12 August 2017

1573-1585

1 reference

12 August 2017

9

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Lopinavir protein binding in vivo through the 12-hour dosing interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Metabolic complications associated with HIV protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1573

10.1517/14656566.6.9.1573

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16086645